This might be due to the inadequate inhibition of miR-330-5p by transient transfection of the inhibitor, or that other downstream targets of RPPH1 rather than miR-330-5p also contribute to the roles of RPPH1 in AML progression. This evidence concerns the gene RPPH1 and acute myeloid leukemia.